Table 1.
Time (hr) | 5-FU dosing | with bolus injection of 5-FU (N = 5) | without bolus injection of 5-FU (N = 5) | P |
---|---|---|---|---|
0 | 1st oral UFT/LV | 0.0±0.0 | 0.0±0.0 | NS |
0.5 | 14.0±31.2 | 1.5±3.4 | NS | |
1 | 37.0±48.9 | 19.8±18.7 | NS | |
2 | 28.5±18.7 | 79.3±64.7 | NS | |
2.5 | bolus injection b) | 81751.0±49135.1 | 67.3±45.2 | <0.05 |
2.75 | 21161.2±4592.7 | 41.4±36.9 | <0.05 | |
3 | 9326.7±2085.7 | 22.4±20.7 | <0.05 | |
3.5 | 1845.7±1308.2 | 14.0±7.6 | <0.05 | |
4 | 485.4±229.3 | 11.0±6.4 | <0.05 | |
8 | 2nd oral UFT/LV | 25.5±10.9 | 5.7±6.6 | <0.05 |
10 | 39.5±14.3 | 22.4±17.3 | NS | |
24 | 4th oral UFT/LV | 27.4±12.0 | 9.4±8.0 | <0.05 |
48 | 7th oral UFT/LV | 31.3±11.5 | 10.4±8.4 | <0.05 |
336 | 15.8±11.9 | 0.0±0.0 | <0.05 |
The values are the mean±SD.
a) Protocol is indicated in Figure 1. “Time 0” means 9:00 on day 1, the time of the first oral administration of UFT/LV at 100 mg x 3 as tegafur/m2/day and 25 mg x 3/day, respectively. The intravenous infusion of CPT-11 at 100 mg/m2 was done from Time = 0.5 hr to 2 hr, and followed by the infusion of l-LV at 15 mg/m2 for 30 min. Immediately thereafter, a bolus of 5-FU was injected at a dose of 500 mg/m2.
b) Five of 10 patients were not injected with a bolus of 5-FU.